Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (1463)	9/18/1998 9:03:00 PM
From: William Whitehead Jr.	Read Replies (2) \| Respond to of 2173

I'm new to Amylin and got into it as a result of another diabetes related stock. I came across the following, it was published in the September 11th issue of Investor Digest. It quotes the Fagan Report (on page headed what the Market Letters) say - "the advisory first issued a buy recommendation when the stock traded at $12.50. It predicted Amylin would be a $100 stock. Note the current price. We've covered the ups and down - mostly downs of Amylin ... we think success in the European trails this January will put the stock back to the low double digits - and a major pharma deal will move it to the high teens or low 20s. Pretty heady stuff for a $3 stock". Article goes on to mention there has been a lot of insider buying. I hope I don't get into trouble sharing this article - didn't see a copyright anywhere. Maybe it might stimulate some interesting posts. Whitey